about
Long-term follow-up after purine analogue therapy in hairy cell leukaemiaMutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemiaA genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemiaT-cell Prolymphocytic Leukemia.Epidemiology and environmental aspects of marginal zone lymphomas.Disease-specific complications of chronic lymphocytic leukemia.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.How I treat prolymphocytic leukemia.B- and T-cell prolymphocytic leukemia: antibody approaches.High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD.Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.Alemtuzumab in T-cell malignancies.Monoclonal antibody therapy of haematological malignancies.Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.Alemtuzumab in lymphoproliferate disorders.Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?Peripheral T-cell lymphomas: diagnosis and management.Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.Alemtuzumab in peripheral T-cell malignancies.Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemiaMature T-cell leukemias.Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas.Prolymphocytic leukemias.The role of alemtuzumab in the management of T-cell malignancies.Alemtuzumab in T-cell lymphoproliferative disorders.Treatment options for high-risk chronic lymphocytic leukaemia.An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy.Is there a role for hemopoietic stem-cell transplantation in CTCL?The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.Role of antibody therapy in lymphoid malignancies.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Outpatient-based therapy of oral fludarabine and subcutaneous alemtuzumab for asian patients with relapsed/refractory chronic lymphocytic leukemia.Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.
P50
Q26776327-E67494A9-2500-4C6A-9F98-5C61EB19C3ACQ27851638-4C0A71F1-66B2-4B79-AB0E-E77ECD7EEEDEQ28943318-0D9132E9-EFD1-4BDE-864B-E831A826D76CQ28943555-3A514DF0-DB03-4C12-BAC7-D0B8CBC57B67Q30235099-2C53D0A6-C646-4385-AE16-5AFAB3682842Q30235306-2B92E4DF-A1C0-4BBC-914B-5999FA26E837Q33382388-946E762B-4DD5-4D70-BC74-A44E8A3EA691Q33411127-1B1BA701-860E-4C62-803F-CD6B52509824Q33416550-0829B137-B85F-4162-BB59-9B47424D1607Q33474151-2F92CF34-8939-4D51-B240-E5F3246B7F5FQ34052075-8DEBDD5C-5436-4B8B-A324-2DAA35F488E7Q34278198-53857278-00C5-4330-AC9E-C631BF9004CEQ34317127-278149A9-24A0-4158-B952-FEAF3C3DED98Q34320319-0C76EF01-B391-4059-9177-6BFAE73AD67DQ34462315-08B5755F-20F4-47F2-A1F3-4FAB272855ACQ34785883-D33723DF-24C5-402E-8272-86FB01CCE5B1Q34796913-B6573FD3-58B9-4BEC-881A-F440CAF6B6E6Q34974068-BD6369E3-2FCD-4BAC-9C83-DFE53BD6C423Q35123154-438E2863-F31D-4995-834F-6A43358F6957Q35161475-B56FAE9A-6E62-4691-B288-8124380113ADQ35204124-E5BC02BA-8564-4E52-BC49-AB6F0536FCF2Q35622810-52877500-31AB-4AAA-9980-7951D0B32EE6Q35812737-B98F9B91-2B61-4C76-92CF-ADF68A6AE11DQ35904058-5F02B1EF-829E-44DA-B136-EAA91B0760AFQ36104721-3349609B-4914-4CD0-9382-669663575940Q36141922-46698457-07D4-4962-B62C-39BC249185D4Q36246565-801575F3-5120-4228-BF88-74EEF521FD19Q36426136-05E5CA3B-3E75-4DDC-9B86-FAF5451DA219Q36449687-E4F1A8FF-F7C3-4405-A00C-C74AEFDD448DQ36486487-71CD0C81-3AAF-45C2-8EAA-74DB8B5A5E06Q36602064-2D7CB3E3-6C50-4656-9171-52F77721E1B6Q36612587-E1025AB5-52B5-401E-B3F4-B0117BAE70CBQ36799737-FC5BE032-F6EC-4FB8-8F01-FA1897E35182Q36808914-8AD499BD-A534-4AAA-A1B0-BD2362995C1EQ36948475-22750C8E-6768-468B-B280-C64DA8A53A96Q36974021-F15BD8BC-FC7E-4AC7-B5FC-65460BEF4C77Q37134417-49DD2D35-2E13-4BB2-B692-6262BA93009EQ37423850-9C809883-8A56-474B-A271-AF25EE93783CQ37623386-3AA4C462-E556-4476-B942-DA2CDFE9A3A5Q37637724-B5704D64-3D94-4723-8AB8-FAF186E81F1A
P50
name
Claire E. Dearden
@ast
Claire E. Dearden
@en
Claire E. Dearden
@nl
type
label
Claire E. Dearden
@ast
Claire E. Dearden
@en
Claire E. Dearden
@nl
prefLabel
Claire E. Dearden
@ast
Claire E. Dearden
@en
Claire E. Dearden
@nl